Monthly Newsletter

Results from Ara h 6 ImmunoCAP testing can act as an aid to help specialists and other clinicians better understand patients’ risk factors as part of tailored allergy treatment or management plans. In some cases, it could reduce the need for oral food challenges, a testing method where a healthcare professional feeds a patient food in measured doses to see if it triggers an allergic reaction.

Testing a patient’s sensitivity to Ara h 6 can play a critical role in understanding the likelihood of a future life-threatening reaction,” said Rebecca Rosenberger, MMSc, PA-C, senior manager, clinical affairs and education, Thermo Fisher Scientific. “Adding the Ara h 6 test to the existing ImmunoCAP peanut component assays enables us to provide a more complete view of a patient’s overall peanut sensitization, including whether a patient is at risk for cross-reactivity.”

Advanced diagnostic capabilities for peanut allergies can contribute to better outcomes for allergy sufferers, especially young children. Patients should consult with their healthcare professional or healthcare provider to get tested for individual peanut components. This knowledge helps the clinician understand potential risks, leads to more informed allergy management, and provides renewed peace of mind for patients and parents.